| GeneLibs

题目:: Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.
作者:: Eisfeld(A-K),Kohlschmidt(J),Schwind(S),Nicolet(D),Blachly(J S),Orwick(S),Shah(C),Bainazar(M),Kroll(K W),Walker(C J),Carroll(A J),Powell(B L),Stone(R M),Kolitz(J E),Baer(M R),de la Chapelle(A),Mrózek(K),Byrd(J C),Bloomfield(C D)
状态:: 发布时间2016-11-15 , 更新时间 2016-11-16
期刊:: Leukemia
摘要:: Core-binding factor acute myeloid leukemia (CBF-AML) is defined by the presence of either t(8;21)(q22;q22)/RUNX1-RUNX1T1 or inv(16)(p13.1q22)/t(16;16)(p13.1;q22)/CBFB-MYH11. The resulting fusion genes require a 'second hit' to initiate leukemogenesis. Mutation assessment of 177 adults with CBF-AML, including 68 with t(8;21) and 109 with inv(16)/t(16;16), identified not only mutations well-known in CBF-AML, but also mutations in the CCND1 and CCND2 genes, which represent novel frequent molecular alterations in AML with t(8;21). Altogether, CCND1 (n=2) and CCND2 (n=8) mutations were detected in 10 (15%) patients with t(8;21) in our cohort. A single CCND2 mutation was also found in one (0.9%) patient with inv(16). In contrast, CCND1 and CCND2 mutations were detected in only 11 (0.77%) of 1,426 non-CBF-AML patients. All CCND2 mutations cluster around the highly conserved amino acid residue threonine 280 (Thr280). We show that Thr280Ala mutated CCND2 leads to increased phosphorylation of the retinoblastoma protein, thereby causing significant cell cycle changes and increased proliferation of AML cell lines. The identification of CCND1 and CCND2 mutations as frequent mutational events in t(8;21) AML may provide further justification for cell cycle-directed therapy in this disease.Leukemia accepted article preview online, 15 November 2016. doi:10.1038/leu.2016.332.
语言:: eng
DOI:: 10.1038/leu.2016.332

文献库文献相关信息

DataTable pData

联系方式

微信公众号

文献库 文献相关信息

DataTable pData

联系方式

微信公众号

文献库文献相关信息